ESR1 and metastatic neoplasm: In addition, we found that the V534E mutation, characterized in metastatic tumors progressing after multiple lines of endocrine therapy including SERDs [36], prevents ERα SUMOylation and results in increased transcription of estrogen target genes in the presence of ICI182,780, without increasing basal activity.